{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:17:54Z","timestamp":1792603074910,"version":"4.5.0"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Aim<\/jats:title><jats:p>Long acting injectable (LAI) antipsychotics are an alternative to oral antipsychotic (OAP) treatment and may be beneficial for patients in the early stages of schizophrenia. This study aims to provide a comprehensive review on the efficacy of first-generation and second-generation LAI antipsychotics in recent-onset, first-episode, and early psychosis patients.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>MEDLINE, EMBASE, PsycINFO, and Web of Science Core databases were used to search for studies that used LAIs in early psychosis patients. Studies published up to 06 Jun 2019 were included with no language restrictions applied. Inclusion criteria were a diagnosis of schizophrenia or related disorder, where patients were in their first episode or had a duration of illness \u22645 years.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>33 studies were included: 8 RCTs, 4 post-hoc analyses, 2 case reports, and 19 naturalistic studies. The majority of studies evaluated risperidone LAIs (N = 14) and paliperidone palmitate (N = 10), while the remainder investigated fluphenazine decanoate (N = 3), flupentixol decanoate (N = 2), and aripiprazole (N = 1). Two studies did not specify the LAI formulation used, and one cohort study compared the efficacy of multiple different LAI formulations.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>While the majority of data is based on naturalistic studies investigating risperidone LAIs or paliperidone palmitate, LAIs may be an effective treatment for early psychosis patients in terms of adherence, relapse reduction, and symptom improvements. There is still a need to conduct more high quality RCTs that investigate the efficacy of different LAI formulations in early psychosis patients.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0267808","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T17:37:00Z","timestamp":1651253820000},"page":"e0267808","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review"],"prefix":"10.1371","volume":"17","author":[{"given":"Lulu","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"C\u00e1zares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-1574","authenticated-orcid":true,"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"pone.0267808.ref001","volume-title":"Schizophrenia. StatPearls.","author":"M Hany","year":"2019"},{"issue":"1","key":"pone.0267808.ref002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4088\/JCP.v69n0114","article-title":"Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.","volume":"69","author":"DO Perkins","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"pone.0267808.ref003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fpsyt.2019.00067","article-title":"Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.","volume":"10","author":"P Bozzatello","year":"2019","journal-title":"Front Psychiatry."},{"issue":"4","key":"pone.0267808.ref004","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","article-title":"Medication adherence of individuals with a first episode of psychosis.","volume":"106","author":"EL Coldham","year":"2002","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"pone.0267808.ref005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1034\/j.1600-0447.2000.102003203.x","article-title":"Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects.","volume":"102","author":"H Verdoux","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"pone.0267808.ref006","doi-asserted-by":"crossref","first-page":"100221","DOI":"10.1016\/j.abrep.2019.100221","article-title":"A retrospective study of the role of long-acting injectable antipsychotics in preventing rehospitalization in early psychosis with cannabis use.","volume":"10","author":"E Rozin","year":"2019","journal-title":"Addictive behaviors reports."},{"key":"pone.0267808.ref007","doi-asserted-by":"crossref","first-page":"20451253211027449","DOI":"10.1177\/20451253211027449","article-title":"The effect of non-adherence to antipsychotic treatment on rehospitalization in patients with psychotic disorders","volume":"11","author":"H Abdullah-Koolmees","year":"2021","journal-title":"Therapeutic advances in psychopharmacology"},{"issue":"3","key":"pone.0267808.ref008","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/QMH.0000000000000223","article-title":"Predictors of Cost and Incidence of 30-Day Readmissions Following Hospitalizations for Schizophrenia and Psychotic Disorders: A Nationwide Analysis.","volume":"28","author":"RJ Wani","year":"2019","journal-title":"Quality management in health care."},{"issue":"1","key":"pone.0267808.ref009","doi-asserted-by":"crossref","first-page":"e013881","DOI":"10.1136\/bmjopen-2016-013881","article-title":"Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode","volume":"7","author":"D Keating","year":"2017","journal-title":"BMJ open"},{"issue":"5","key":"pone.0267808.ref010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11920-013-0355-6","article-title":"Antipsychotic and psychostimulant drug combination therapy in attention deficit\/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.","volume":"15","author":"D Linton","year":"2013","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"pone.0267808.ref011","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1503\/jpn.130288","article-title":"Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment","volume":"39","author":"D Elbe","year":"2014","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"pone.0267808.ref012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.15586\/jptcp.v27i3.681","article-title":"Treatment algorithm for the use of psychopharmacological agents in individuals prenatally exposed to alcohol and\/or with diagnosis of fetal alcohol spectrum disorder (FASD).","volume":"27","author":"M Mela","year":"2020","journal-title":"Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique"},{"issue":"4","key":"pone.0267808.ref013","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/YIC.0000000000000310","article-title":"Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis.","volume":"35","author":"A Abdel-Baki","year":"2020","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"pone.0267808.ref014","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/eip.12278","article-title":"Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.","volume":"10","author":"GL Stevens","year":"2016","journal-title":"Early Interv Psychiatry"},{"issue":"5","key":"pone.0267808.ref015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","article-title":"Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.","volume":"35","author":"D Lin","year":"2021","journal-title":"CNS Drugs."},{"issue":"suppl 3","key":"pone.0267808.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.","volume":"77","author":"CU Correll","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"pone.0267808.ref017","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.psychres.2016.10.053","article-title":"Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials.","volume":"246","author":"T Kishi","year":"2016","journal-title":"Psychiatry Res"},{"issue":"3","key":"pone.0267808.ref018","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/eip.12027","article-title":"Long-acting injectable antipsychotics in early psychosis: a literature review.","volume":"7","author":"R Emsley","year":"2013","journal-title":"Early Interv Psychiatry"},{"key":"pone.0267808.ref019","first-page":"560836","article-title":"Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons","volume":"2012","author":"B Kim","year":"2012","journal-title":"Schizophr Res Treatment"},{"issue":"2","key":"pone.0267808.ref020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/YIC.0000000000000249","article-title":"Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review.","volume":"34","author":"M Salgueiro","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"pone.0267808.ref021","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/0004867412470010","article-title":"Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.","volume":"47","author":"M Taylor","year":"2013","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"pone.0267808.ref022","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.","volume":"3","author":"D Moher","year":"2009","journal-title":"Open medicine: a peer-reviewed, independent, open-access journal."},{"issue":"4","key":"pone.0267808.ref023","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-015-1807-1","article-title":"Treatment of clozapine-associated weight gain: a systematic review","volume":"71","author":"Z Whitney","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"pone.0267808.ref024","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"L Tse","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"pone.0267808.ref025","article-title":"Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.","author":"A Abdel-Baki","year":"2019","journal-title":"Early Interv Psychiatry."},{"key":"pone.0267808.ref026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.","volume":"8","author":"G Morken","year":"2008","journal-title":"BMC Psychiatry."},{"issue":"Suppl 1","key":"pone.0267808.ref027","first-page":"S348","article-title":"Efficacy of LAI in first episode psychosis: an observational study\u2014clinical reports.","volume":"27","author":"A Cervone","year":"2015","journal-title":"Psychiatria Danubina."},{"issue":"1","key":"pone.0267808.ref028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/eip.12271","article-title":"Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.","volume":"12","author":"L Alphs","year":"2018","journal-title":"Early Interv Psychiatry"},{"issue":"4","key":"pone.0267808.ref029","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/NMD.0000000000000646","article-title":"Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.","volume":"205","author":"CA Bossie","year":"2017","journal-title":"J Nerv Ment Dis."},{"issue":"5","key":"pone.0267808.ref030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/2045125315600141","article-title":"Two cases of long-acting paliperidone in adolescence","volume":"5","author":"M F\u00e0brega","year":"2015","journal-title":"Therapeutic advances in psychopharmacology"},{"issue":"1","key":"pone.0267808.ref031","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/2211556004666150918194108","article-title":"Decreased Incidence of Readmissions in First Episode Psychosis in Treatment with Long\u2014Acting Injectable Antipsychotics.","volume":"4","author":"AT Privat","year":"2015","journal-title":"Current Psychopharmacology"},{"issue":"1\u20133","key":"pone.0267808.ref032","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"A Schreiner","year":"2015","journal-title":"Schizophr Res"},{"key":"pone.0267808.ref033","first-page":"375","article-title":"Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.","volume":"8","author":"JK Sliwa","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"pone.0267808.ref034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.9740\/mhc.2018.03.056","article-title":"Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis.","volume":"8","author":"EN Titus-Lay","year":"2018","journal-title":"The mental health clinician."},{"issue":"4","key":"pone.0267808.ref035","first-page":"301","article-title":"Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.","volume":"26","author":"J V\u00e1zquez-Bourgon","year":"2014","journal-title":"Ann Clin Psychiatry"},{"key":"pone.0267808.ref036","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S77778","article-title":"Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.","volume":"11","author":"F Zhang","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"pone.0267808.ref037","first-page":"164","article-title":"Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.","volume":"28","author":"P Barrio","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"issue":"1","key":"pone.0267808.ref038","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.schres.2011.06.029","article-title":"Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory","volume":"132","author":"G Bartzokis","year":"2011","journal-title":"Schizophr Res"},{"issue":"1","key":"pone.0267808.ref039","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/eip.12017","article-title":"Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).","volume":"8","author":"V Dubois","year":"2014","journal-title":"Early Interv Psychiatry"},{"issue":"2","key":"pone.0267808.ref040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","article-title":"Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study.","volume":"28","author":"R Emsley","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"pone.0267808.ref041","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.pnpbp.2008.03.012","article-title":"Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting","volume":"32","author":"B Kim","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"pone.0267808.ref042","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10401230701332931","article-title":"Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.","volume":"19","author":"RA Lasser","year":"2007","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"pone.0267808.ref043","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/YIC.0b013e3283347cbf","article-title":"Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.","volume":"25","author":"W Macfadden","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"pone.0267808.ref044","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3371\/CSRP.MACH.061213","article-title":"An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.","volume":"9","author":"A Malla","year":"2016","journal-title":"Clin Schizophr Relat Psychoses."},{"issue":"2","key":"pone.0267808.ref045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0b013e3181d438e2","article-title":"Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures.","volume":"30","author":"O Napryeyenko","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"5 Suppl","key":"pone.0267808.ref046","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0269881105056513","article-title":"Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.","volume":"19","author":"E Parellada","year":"2005","journal-title":"J Psychopharmacol."},{"issue":"1","key":"pone.0267808.ref047","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/JCP.0b013e31820568c6","article-title":"Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable.","volume":"31","author":"J Rabinowitz","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"pone.0267808.ref048","first-page":"184","article-title":"Efficacy and safety of long-acting risperidone on early onset schizophrenia in adolescent patients","volume":"4","author":"L Ruan","year":"2010","journal-title":"African Journal of Pharmacy and Pharmacology"},{"issue":"8","key":"pone.0267808.ref049","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial","volume":"72","author":"KL Subotnik","year":"2015","journal-title":"JAMA psychiatry"},{"issue":"9","key":"pone.0267808.ref050","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.11m06905","article-title":"Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.","volume":"73","author":"PJ Weiden","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"pone.0267808.ref051","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3389\/fpsyt.2019.00935","article-title":"Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis.","volume":"10","author":"G Giordano","year":"2019","journal-title":"Front Psychiatry."},{"issue":"1","key":"pone.0267808.ref052","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archpsyc.1982.04290010048009","article-title":"Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.","volume":"39","author":"JM Kane","year":"1982","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"pone.0267808.ref053","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archpsyc.1977.01770130045004","article-title":"Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.","volume":"34","author":"A Rifkin","year":"1977","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"pone.0267808.ref054","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1037\/0021-843X.107.4.691","article-title":"P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects.","volume":"107","author":"CM Yee","year":"1998","journal-title":"J Abnorm Psychol"},{"issue":"3","key":"pone.0267808.ref055","first-page":"109","article-title":"A prospective study of clinical, biological and functional aspects of outcome in first-episode psychosis: The EONKCS Study.","volume":"21","author":"B Chiliza","year":"2015","journal-title":"South African Journal of Psychiatry"},{"issue":"13","key":"pone.0267808.ref056","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1017\/S0033291715000860","article-title":"Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study.","volume":"45","author":"MR Olivier","year":"2015","journal-title":"Psychol Med"},{"issue":"6","key":"pone.0267808.ref057","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.","volume":"44","author":"H Taipale","year":"2018","journal-title":"Schizophr Bull."},{"issue":"12","key":"pone.0267808.ref058","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.clinthera.2008.12.020","article-title":"Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.","volume":"30","author":"R Emsley","year":"2008","journal-title":"Clin Ther"},{"key":"pone.0267808.ref059","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3389\/fpsyt.2020.00795","article-title":"Neurophysiological Biomarkers in Schizophrenia-P50, Mismatch Negativity, and TMS-EMG and TMS-EEG.","volume":"11","author":"HK Kim","year":"2020","journal-title":"Front Psychiatry."},{"key":"pone.0267808.ref060","doi-asserted-by":"crossref","first-page":"110001","DOI":"10.1016\/j.pnpbp.2020.110001","article-title":"Genetic underpinnings of schizophrenia-related electroencephalographical intermediate phenotypes: A systematic review and meta-analysis","volume":"104","author":"J Hederih","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"pone.0267808.ref061","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1744-859X-10-2","article-title":"Guidelines for rating Global Assessment of Functioning (GAF).","volume":"10","author":"IH Aas","year":"2011","journal-title":"Annals of general psychiatry."},{"key":"pone.0267808.ref062","article-title":"Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis.","author":"L Lian","year":"2021","journal-title":"Early Interv Psychiatry."},{"key":"pone.0267808.ref063","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1192\/bjp.195.52.s20","article-title":"First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.","volume":"52","author":"PM Haddad","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"issue":"1","key":"pone.0267808.ref064","doi-asserted-by":"crossref","first-page":"e53459","DOI":"10.1371\/journal.pone.0053459","article-title":"Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.","volume":"8","author":"HN Boyda","year":"2013","journal-title":"PLoS One."},{"key":"pone.0267808.ref065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fnins.2018.00203","article-title":"Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review.","volume":"12","author":"JWY Yuen","year":"2018","journal-title":"Frontiers in neuroscience"},{"issue":"6","key":"pone.0267808.ref066","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10286-017-0444-4","article-title":"Heart-rate response to alpha2-adrenergic receptor antagonism by antipsychotics","volume":"27","author":"DD Kim","year":"2017","journal-title":"Clinical autonomic research: official journal of the Clinical Autonomic Research Society"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:39:26Z","timestamp":1700516366000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267808"}},"subtitle":[],"editor":[{"given":"Kyle J.","family":"Burghardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0267808","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}